Subject:
- Active Substance: Asciminib
- Name: Scemblix®
- Therapeutic area: Chronic myeloid leukemia
- Pharmaceutical company: Novartis Pharma GmbH
Time table:
- Start: 01.10.2022
- Final decision by G-BA: 16.03.2023
Final decision:
- Indication for a minor additional benefit